Laurent Salphati

The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Adrian Folkes, Khatereh Ahmadi, W. Alderton et al. · Journal of Medicinal Chemistry · 2008 · 746 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

GDC-0449—A potent inhibitor of the hedgehog pathway

Kirk Robarge, Shirley A. Brunton, Georgette M. Castanedo et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 387 citations · Full text

Pharmacy, Life Sciences, Medicinal Chemistry +10

Active secretion and enterocytic drug metabolism barriers to drug absorption

Vincent J. Wacher, Laurent Salphati, Leslie Z. Benet · Advanced Drug Delivery Reviews · 1996 · 310 citations

Pharmacy, Pharmaceutics, Pharmacology +16

Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition

Aaron Boudreau, Hans E. Purkey, A. Hitz et al. · Nature Chemical Biology · 2016 · 268 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +13

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

Jeffrey J. Wallin, Kyle A. Edgar, Jane Guan et al. · Molecular Cancer Therapeutics · 2011 · 228 citations

Medicine, Oncology, Pharmacology +16